FindTrial
Sign In

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/ LY3650150 in Adult Participants With Perennial Allergic Rhinitis

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-508817-18-00
Acronym
J2T-MC-KGBT
Enrollment
258
Registered
2024-08-05
Start date
2024-10-08
Completion date
Unknown
Last updated
2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perennial Allergic Rhinitis (PAR)

Brief summary

1. Mean Change From Baseline (CFBL) in Total Nasal Symptom Score (TNSS) at Week 16 Total nasal symptom score was a composite of 4 symptoms (rhinorrhea, nasal congestion, nasal itching and sneezing), each symptom was scored on a scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total score ranged from 0 to 12. The higher the score was, the more severe the symptoms were. [Time Frame: Baseline, Week 16]

Interventions

DRUGLebrikizumab
DRUGPlacebo for Lebrikizumab
DRUGMOMETASONE

Sponsors

Eli Lilly & Co.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
1. Mean Change From Baseline (CFBL) in Total Nasal Symptom Score (TNSS) at Week 16 Total nasal symptom score was a composite of 4 symptoms (rhinorrhea, nasal congestion, nasal itching and sneezing), each symptom was scored on a scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total score ranged from 0 to 12. The higher the score was, the more severe the symptoms were. [Time Frame: Baseline, Week 16]—

Countries

Belgium, Germany, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026